NovoCure Limited (NASDAQ:NVCR) CTO Yoram Palti sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $18.25, for a total value of $547,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Yoram Palti also recently made the following trade(s):

  • On Tuesday, November 7th, Yoram Palti sold 60,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.06, for a total value of $1,263,600.00.
  • On Thursday, November 2nd, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.78, for a total value of $653,400.00.

Shares of NovoCure Limited (NASDAQ NVCR) traded down $0.25 during trading on Monday, hitting $17.05. The stock had a trading volume of 782,941 shares, compared to its average volume of 853,971. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.30 and a current ratio of 5.90. NovoCure Limited has a fifty-two week low of $6.00 and a fifty-two week high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. The business had revenue of $50.10 million for the quarter, compared to analysts’ expectations of $43.45 million. NovoCure Limited had a negative return on equity of 57.68% and a negative net margin of 47.45%. The business’s quarterly revenue was up 130.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.39) EPS. research analysts expect that NovoCure Limited will post -0.63 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/13/novocure-limited-nvcr-cto-sells-547500-00-in-stock.html.

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc increased its position in NovoCure Limited by 8.5% in the 2nd quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 1,092 shares during the period. American International Group Inc. increased its position in shares of NovoCure Limited by 7.1% during the 1st quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock valued at $253,000 after purchasing an additional 2,065 shares during the period. Bank of New York Mellon Corp increased its position in shares of NovoCure Limited by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock valued at $1,406,000 after purchasing an additional 2,480 shares during the period. California State Teachers Retirement System increased its position in shares of NovoCure Limited by 2.6% during the 2nd quarter. California State Teachers Retirement System now owns 102,309 shares of the medical equipment provider’s stock valued at $1,770,000 after purchasing an additional 2,600 shares during the period. Finally, Teachers Advisors LLC increased its position in shares of NovoCure Limited by 3.3% during the 1st quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock valued at $800,000 after purchasing an additional 3,125 shares during the period. Institutional investors and hedge funds own 36.21% of the company’s stock.

A number of research firms have commented on NVCR. Zacks Investment Research downgraded NovoCure Limited from a “buy” rating to a “hold” rating in a report on Friday. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price (down previously from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Mizuho began coverage on NovoCure Limited in a report on Wednesday, September 6th. They set a “buy” rating and a $25.00 target price on the stock. BidaskClub raised NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $19.00 target price (up previously from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. NovoCure Limited currently has an average rating of “Buy” and an average target price of $21.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.